On March 24, 2021 Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, reported that it will present at the Spring 2021 Oncology Investor Conference on March 29, 2021 (Press release, Genprex, MAR 24, 2021, View Source [SID1234577090]). Genprex’s President and Chief Executive Officer, Rodney Varner, will deliver a virtual company overview to investors, including its novel gene therapies for non-small cell lung cancer and diabetes.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: Oncology Investor Conference (Virtual)

Date: The conference will take place virtually March 29 – April 2, 2021

Presentation Date: Monday, March 29

Presentation Time: 2 p.m. Eastern Daylight Time

Registration Link: http://bit.ly/3qT3ztc

The Company invites investors to join the webcast presentation, and Mr. Varner will be available for one-on-one meetings with investors throughout the conference.